All HLB Group affiliates are unable to escape a downward trend in tandem during the trading session on the 28th. Rather than selling pressure being concentrated on a specific stock, most bio and pharmaceutical related stocks are declining together, indicating that investment sentiment across the entire group is contracting.

◇ All Affiliates Decline... HLB Genex and HLB Innovation Post Larger Drops

Based on intraday trading, the trends for each stock are as follows.

• HLB: Traded at 30,100 won, down 1,350 won from the previous trading day (decline rate of 4.29%). It opened at 31,450 won and rose to 32,200 won during the session, but selling volume increased, pushing it down to as low as 29,800 won.
• HLB Genex: Down 5.09% to 1,530 won, with the current price near the intraday low.
• HLB Innovation: Down 4.99% to 7,810 won.
• HLB Therapeutics: Down 4.12% to 1,630 won.
• HLB Biostep: Down 3.78% to 1,732 won.
• HLB Panagine: Down 3.33% to 1,016 won.
• HLB Pan: Down 2.89% to 3,865 won.
• HLB Life Sciences: Down 60 won to 2,140 won, a 2.73% decline.
• HLB Global: Down 2.80% to 1,181 won.
• HLB Pharmaceutical: Down 2.09% to 8,440 won, with a relatively limited decline.

Although HLB Pharmaceutical had a small decline, its intraday volatility was notable. It opened at 8,750 won, rose to 9,680 won, and then dropped to 8,260 won. Its trading volume exceeded 750,000 shares, the highest among HLB affiliate stocks.

◇ Group-wide Supply and Demand Changes Cited as Cause... Key Points to Watch Going Forward

Given that all major affiliate stocks are on a downward trend, it is analyzed that group-wide supply and demand changes are being reflected in stock prices rather than factors tied to individual stocks. However, it is difficult to definitively conclude the specific cause of the simultaneous decline based solely on current price movements.

Key points to confirm going forward include whether HLB can secure support around the intraday low of 29,800 won, whether the surge in HLB Pharmaceutical's trading volume leads to additional selling, and whether HLB Genex and HLB Therapeutics will see expanded short-term volatility as they trade at low price levels.

[This is an article written with the assistance of AI. This article is informational material based on securities firm reports and regulatory filings, and does not recommend the purchase or sale of any specific stock. Target prices and earnings forecasts may change depending on market conditions and the corporate management environment, so investment decisions and responsibilities rest with the investor.]